Pharma Stocks To Buy 2017 -

: Led the industry in R&D spending, focused heavily on its blockbuster immunotherapy Keytruda .

: A top pick for dividends (yielding ~4.2%) and growth, with shares rising 45% in 2017 driven by Humira and its cancer drug pipeline. pharma stocks to buy 2017

The year’s biggest winners were often clinical-stage companies that secured major regulatory wins or licensing deals. : Led the industry in R&D spending, focused

: Gained 103% , evolving from a rare-disease specialist into a large-cap biotech giant. Blue-Chip & Dividend Leaders pharma stocks to buy 2017

: Maintained its lead in prescription sales and remained a "Strong Buy" due to its robust clinical pipeline and steady dividend.

: Delivered a 516% return as it dominated its niche in the metabolic disease market.